Brotz-Oesterhelt, H., Beyer, D., Kroll, H., Endermann, R., Ladel, C., Schroeder, W., Hinzen, B., Raddatz, S., Paulsen, H., Henninger, K., Bandow, J.E., Sahl, H. and Labischinski, H. (2005) Dysregulation of Bacterial Proteolytic Machinery by a New Class of Antibiotics. Nature Medicine, 11, 1082-1087.
https://doi.org/10.1038/nm1306

has been cited by the following article:

• TITLE: Trisubstituted Aryl Cyclohexanecarboxylates (TACC): A Simple, New Molecular Scaffold for Antibiotics Design

  AUTHORS: Olusegun B. Olubanwo, Arianna Kazez, Daniel W. Carney, Jason K. Sello

  KEYWORDS: Cyclohexanecarboxylate, Oxocyclohexanecarboxylate, ClpP Activator, Bacillus Subtilis, Antibacterial, Antibiotics, Pseudo-Robinson Protocol, Pharmacophores, Clp Protease

  JOURNAL NAME: International Journal of Organic Chemistry, Vol.9 No.3, September 18, 2019

  ABSTRACT: A new class of potential antibacterial agents has been synthesized on a new molecular scaffold of cyclohexane carboxylate. We have tagged this new class of compounds TACCs (Trisubstituted Aryl Cyclohexanecarboxylate). These new molecules are structural analogues of an Activators of Self-Compartmentalizing Proteases 4 and 5 (ACP 4 and 5), and were synthesized to circumvent the drug-like property (drug-ability) challenges and liability noted in ACP 4 and 5. A pseudo-Robinson annulation protocol was used to furnish this new class of potential antibiotics. Structure-activity relationship (SAR) study was done to identify the pharmacophore(s) in this molecular scaffold. A selection of these compounds was used in our preliminary antibacterial inhibitory activities’ studies on Bacillus mycoides and Bacillus subtilis. These preliminary studies show that the TACCs exhibited equal, and in some cases better, antibacterial activity than ACP 4 and 5.